TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

Hope S Rugo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.